z-logo
Premium
Evaluation of engraftment syndrome in children following full‐matched related donor hematopoietic stem cell transplantations
Author(s) -
İleri Talia,
Ünal İnce Elif,
Çakmaklı Hasan,
Uysal Zümrüt,
Gençtürk Zeynep,
Ertem Mehmet
Publication year - 2016
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.12708
Subject(s) - medicine , rash , univariate analysis , incidence (geometry) , hematopoietic stem cell transplantation , multivariate analysis , hematopoietic stem cell , disease , stem cell , pediatrics , surgery , haematopoiesis , physics , biology , optics , genetics
Abstract The term “ ES ” has been widely used for describing a clinical condition consisting of skin rash, fever, and weight gain that occur during neutrophil recovery period following HSCT . In this study, the incidence, clinical features, risk factors, and outcomes of ES were evaluated in 169 children following allogeneic HSCT from full‐matched related donor according to the Spitzer criteria. Seventeen patients (10.1%) presented with clinical conditions suggesting ES . In both univariate and multivariate analysis underlying malignant disease and early release of monocytes to the PB, and in univariate analysis using only CsA for GVHD prophylaxis were found to be the significant risk factors for the development of ES . Patients with ES experienced significantly higher incidence of acute and chronic GVHD and propensity toward a higher rate of TRM. OS did not differ between the patient groups. Thirteen of 17 patients received steroid therapy, and all but one patient responded to therapy. Monitoring for early detection of ES and early intervention with steroid therapy is the key for recovery. The most crucial approach for this purpose mainly is to find out and use the most useful and feasible diagnostic criteria for routine medical practice.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here